Amir T. Fathi, MD, MPH, Massachusetts General Hospital, Boston, MA, gives an overview of how novel targeted agents and individualized treatment approaches are improving outcomes for patients with acute myeloid leukemia (AML). Dr Fathi first highlights FLT3 inhibitors that are available to patients, including midostaurin and gilteritinib. Following this, Dr Fathi discusses agents available to patients with IDH1 and IDH2 mutations, and further comments on the potential role of menin inhibitors in the future treatment of AML. This interview took place at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO) held in Houston, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.